Latest Commercialisation News

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

EMVision Medical Devices has begun a pivotal aeromedical study with the Royal Flying Doctor Service to test its portable First Responder brain scanner in remote emergency settings. The trial aims to validate device usability and workflow integration ahead of commercial rollout.

Provaris Energy’s 2025 AGM highlights strategic progress in hydrogen and CO2 storage technologies, focusing on European market expansion and a refined licensing business model.

PPK Group reports record revenue at Craig International Ballistics and advances lithium sulfur battery technology, while preparing for a CEO transition and focusing on sovereign manufacturing.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Eclipse Metals has engaged BGR Group, a leading U.S. government relations firm, to strengthen its strategic positioning and funding prospects for its Greenland rare earth projects, advancing its role in Western critical minerals supply chains.

Straker Ltd’s H1 FY26 results reveal a strategic shift from legacy translation services to AI-driven specialised language models, anchored by a $28 million partnership with IBM. Despite a 15% revenue decline, the company maintains positive adjusted EBITDA and a strong balance sheet.

Straker Ltd reports a solid first half of FY26 with positive EBITDA and a renewed IBM partnership, despite a 15% revenue decline amid challenging market conditions.

White Energy Company Limited has launched a 5-for-12 partially underwritten entitlement offer at $0.027 per share, aiming to raise approximately $3.5 million to fund mineral exploration and corporate needs. Major shareholders and directors have committed to participate, while the offer excludes ineligible shareholders and related parties.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

Omega Oil and Gas has secured a significant 19.43% equity interest in Elixir Energy, strengthening its foothold in Queensland’s Taroom Trough ahead of key drilling activities in 2026.